Based on such studies, we speculate that combining BMI1 inhibition with standard‐of‐care chemotherapeutic regimens in RMS may both be well‐tolerated and result in greater inhibition of tumor growth, though further studies are needed to investigate this hypothesis. This evidence concerns the gene BMI1 and neoplasm.